Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$7.25 USD
-0.60 (-7.64%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.24 -0.01 (-0.14%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KYTX 7.25 -0.60(-7.64%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYTX
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
3 Best Stocks to Buy Now, 7/18/2024, According to Top Analysts
Buy Rating on Kyverna Therapeutics: KYV-101’s Promising Clinical Advances and Market Potential